Celator Pharmaceuticals

Celator Pharmaceuticals is a biopharmaceutical company dedicated to developing therapies for cancer treatment. The company focuses on CombiPlex, a drug ratio technology platform used to develop combination therapies. Its products include CPX-1 (Irinotecan HCl-Floxuridine) for the treatment of colorectal cancer and CPX-351 (Cytarabine-Daunorubicin) for the treatment of acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc., formerly known as Celator Technologies, Inc., was founded in 2000 and is headquartered in Princeton, New Jersey.